Genentech/Roche and Cure SMA to Co-Host Webinar

On Monday, March 11th, at 12pm CST (10am PST/11am MST/1pm EST) Genentech/Roche and Cure SMA will co-host a webinar for the SMA community. During the webinar, you’ll hear from Genentech/Roche on their history working with the SMA community, and their investigational medicine risdiplam. You’ll hear updates on their clinical trials in pre-symptomatic & Types 1, 2 & 3.

The 60-minute webinar will also include a Q&A session. We encourage you to submit your questions when you register, so that we can plan to answer as many of them as possible. We look forward to you joining us!

Please note that this webinar is intended for U.S. audiences only.

Register now 

About Risdiplam

Risdiplam is an investigational, oral medicine that is systemically distributed and designed to increase SMN protein levels in the central nervous system (CNS) and throughout the body. It is designed to help the SMN2 gene produce more functional SMN protein, to better support motor neurons and muscle function. Roche and Genentech are leading the clinical development of risdiplam in collaboration with the SMA Foundation and PTC Therapeutics.

Read a recent update on risdiplam 

Do you like what you're reading?

Help make a difference in the lives of people affected by spinal muscular atrophy.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top